Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About NAGE Interactive Breakdown Better Bets vs. NAGE Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Niagen Bioscience (NAGE)

Market Price (10/31/2025): $7.07 | Market Cap: $560.3 Mil
Sector: Health Care | Industry: Biotechnology

Niagen Bioscience (NAGE)

Market Price (10/31/2025): $7.07
Market Cap: $560.3 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10%		  Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 34x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 27x, P/EPrice/Earnings or Price/(Net Income) is 32x
1 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 36%		  
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18%		  
0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10%
1 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 36%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18%
3 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 34x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 27x, P/EPrice/Earnings or Price/(Net Income) is 32x

Market Valuation & Key Metrics

NAGES&P 500
REVENUE GROWTHVERY GOOD
Rev LTM ($ Bil)0.1
Rev Chg Q36.8%6.4%
Rev Chg LTM35.9%5.4%
Rev Chg 3Y Avg19.6%5.3%
PROFITABILITYFAIR
Op Inc LTM ($ Bil)0.0
CFO LTM ($ Bil)0.0
Net Inc LTM ($ Bil)0.0
Op Mgn LTM14.3%18.7%
CFO/Rev LTM18.2%20.4%
Net Inc Mgn15.2%12.8%
VALUATIONHIGH
P/S4.83.2
P/CFO26.415.5
P/FCF26.820.6
P/E31.623.6
STABILITYVERY GOOD
Debt/Equity0.010.21
Cash/Assets0.660.07

NAGE Stock

   
   
   
   
   
   
   
Factor Drivers of Stock Movement
The -6.0% change in NAGE stock from 5/1/2025 to 10/30/2025 was primarily driven by a -53.3% change in the company's P/E Multiple.

501202510302025Change
Stock Price ($)7.567.11-5.95%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)99.60116.3016.77%
Net Income Margin (%)8.58%15.24%77.57%
P/E Multiple68.0431.78-53.29%
Shares Outstanding (Mil)76.9579.25-2.98%
Cumulative Contribution-6.04%

LTM = Last Twelve Months as of date shown
null

null
null

null

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
NAGE Return------0%
Peers Return-15%-9%-6%-3%-3%-16%-43%
S&P 500 Return16%27%-19%24%23%16%110%

Monthly Win Rates [3]
NAGE Win Rate-----67% 
Peers Win Rate18%15%23%31%22%51% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
NAGE Max Drawdown------ 
Peers Max Drawdown-20%-13%-14%-15%-30%-27% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, APM, BBOT, GDTC, HIND.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/30/2025 (YTD)

How Low Can It Go

NAGE has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Unique KeyEventXLVS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-16.1%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven19.1%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven599 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-28.8%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven40.4%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven116 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-15.8%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven18.8%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven326 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-40.6%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven68.3%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1100 days1480 days

Compare to


In The Past

SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Niagen Bioscience (NAGE)

Better Bets than Niagen Bioscience (NAGE)

 NAGEBetter Performance than NAGE
MetricValueIndustry (Biotechnology)
Rev Chg LTM35.9%BBIO (62.5%), MDGL (3422.0%), CYTK (2635.7%), RYTM (53.5%), MRUS (59.8%)
Rev Chg 3Y Avg19.6%ALNY (40.8%), INSM (22.8%), NBIX (24.6%), BBIO (727.6%), HALO (35.5%)
Op Mgn LTM14.3%ABBV (23.5%), AMGN (23.5%), GILD (37.4%), REGN (26.7%), BIIB (24.8%)
CFO/Rev LTM18.2%ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (35.6%)
FCF/Rev LTM18.0%ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (27.2%)
Total Yield3.1%ABBV (3.7%), AMGN (7.4%), GILD (7.0%), VRTX (3.4%), REGN (7.2%)
 NAGEBetter Performance than NAGE
MetricValueAll Other Sectors
Rev Chg LTM35.9%NVDA (71.6%), PLTR (38.8%), MU (48.9%), APP (48.2%), APH (47.4%)
Rev Chg 3Y Avg19.6%NVDA (92.0%), AVGO (24.0%), PLTR (25.7%), MU (20.3%), SHOP (26.0%)
Op Mgn LTM14.3%NVDA (58.1%), AAPL (31.9%), MSFT (46.3%), GOOGL (32.2%), AVGO (39.0%)
CFO/Rev LTM18.2%NVDA (46.6%), AAPL (26.6%), MSFT (50.0%), GOOGL (39.3%), AVGO (42.4%)
FCF/Rev LTM18.0%NVDA (43.6%), AAPL (23.5%), MSFT (26.6%), GOOGL (19.1%), AVGO (41.6%)
Total Yield3.1%MSFT (3.3%), GOOGL (3.9%), META (3.8%), JPM (6.6%), WMT (3.5%)
 Best Bets In Health Care Sector
 NAGERPRX HALO CPRX BMY LNTH PBH BIIB PFE EW ILMN
What You Pay           
P/E31.815.314.112.315.414.014.013.612.811.812.4
P/EBIT33.88.111.010.59.39.69.010.110.329.210.3
What You Get           
Rev Chg Q36.8%7.7%40.8%19.4%2.8%-4.1%-6.6%2.8%10.3%11.9%-4.8%
Rev Chg LTM35.9%3.0%35.0%28.5%1.3%5.7%0.6%4.8%13.5%9.1%-3.3%
Rev Chg 3Y Avg19.6%0.8%35.5%49.9%1.0%34.3%0.8%-0.9%-12.4%3.0%-3.0%
FCF/Rev 3Y Avg7.1%113.4%43.4%38.9%29.0%26.1%21.6%17.0%13.8%11.9%9.0%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

Trade Ideas

Select past ideas related to NAGE. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		5.9%5.9%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		16.1%16.1%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		2.6%2.6%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		14.2%14.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		15.2%15.2%-8.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		5.9%5.9%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		16.1%16.1%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		2.6%2.6%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		14.2%14.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		15.2%15.2%-8.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1INBXInhibrx Biosciences176.8%409.8%
2PUMPProPetro71.2%16.2%
3RNAAvidity Biosciences43.5%139.6%
4DYNDyne Therapeutics42.8%-0.0%
5GCIGannett39.3%3.8%
6FORMFormFactor38.3%34.7%
7MBXMBX Biosciences35.1%18.2%
8BBNXBeta Bionics33.8% 
9GHGuardant Health33.3%202.5%
10LUMNLumen Technologies32.7%94.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-75.2%5106.3%
2LRNStride-56.1%-35.8%
3NTLAIntellia Therapeutics-52.6%5.2%
4FMCFMC-48.7%-66.6%
5FIFiserv-47.4%-68.3%
6VRNSVaronis Systems-43.8%-21.2%
7THRYThryv-33.4%-44.8%
8NFENew Fortress Energy-30.5%-91.9%
9AKBAAkebia Therapeutics-29.5%10.5%
10UAMYUnited States Antimony-28.9%371.2%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PRAXPraxis Precision Medicines279.1%161.2%
2INBXInhibrx Biosciences131.0%409.8%
3PUMPProPetro99.6%16.2%
4DYNDyne Therapeutics88.4%-0.0%
5VICRVicor85.4%89.2%
6CELCCelcuity74.6%503.2%
7GLUEMonte Rosa Therapeutics73.5%87.5%
8NVTSNavitas Semiconductor72.1%251.8%
9LUMNLumen Technologies70.3%94.7%
10BALYBallys63.4%4.1%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical-62.9%5106.3%
2LRNStride-53.8%-35.8%
3FMCFMC-51.0%-66.6%
4FIFiserv-48.3%-68.3%
5NFENew Fortress Energy-43.6%-91.9%
6VGVenture Global-41.7% 
7OGNOrganon-40.2%-55.0%
8VRNSVaronis Systems-39.5%-21.2%
9ITGRInteger-38.5%-52.2%
10LENZLENZ Therapeutics-37.9%5.5%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1INBXInhibrx Biosciences176.8%409.8%
2PUMPProPetro71.2%16.2%
3RNAAvidity Biosciences43.5%139.6%
4DYNDyne Therapeutics42.8%-0.0%
5GCIGannett39.3%3.8%
6FORMFormFactor38.3%34.7%
7MBXMBX Biosciences35.1%18.2%
8BBNXBeta Bionics33.8% 
9GHGuardant Health33.3%202.5%
10LUMNLumen Technologies32.7%94.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-75.2%5106.3%
2LRNStride-56.1%-35.8%
3NTLAIntellia Therapeutics-52.6%5.2%
4FMCFMC-48.7%-66.6%
5FIFiserv-47.4%-68.3%
6VRNSVaronis Systems-43.8%-21.2%
7THRYThryv-33.4%-44.8%
8NFENew Fortress Energy-30.5%-91.9%
9AKBAAkebia Therapeutics-29.5%10.5%
10UAMYUnited States Antimony-28.9%371.2%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Niagen Bioscience

Financials

NAGEVRTXAPMBBOTGDTCHINDMedian
NameNiagen B.Vertex P.Aptorum BridgeBi.CytoMed .Vyome  
Mkt Price7.11419.891.4712.002.155.586.35
Mkt Cap0.6107.8----54.2
Rev LTM11611,419-0--116
Op Inc LTM17-199--93---93
FCF LTM213,500--60--21
FCF 3Y Avg81,984----996
CFO LTM213,846--60--21
CFO 3Y Avg82,324----1,166

Growth & Margins

NAGEVRTXAPMBBOTGDTCHINDMedian
NameNiagen B.Vertex P.Aptorum BridgeBi.CytoMed .Vyome  
Rev Chg LTM35.9%10.5%----23.2%
Rev Chg 3Y Avg19.6%11.0%----15.3%
Rev Chg Q36.8%12.1%----24.5%
QoQ Delta Rev Chg LTM7.8%2.9%----5.3%
Op Mgn LTM14.3%-1.7%----6.3%
Op Mgn 3Y Avg0.3%26.5%----13.4%
QoQ Delta Op Mgn LTM2.1%2.0%----2.1%
CFO/Rev LTM18.2%33.7%----26.0%
CFO/Rev 3Y Avg7.3%22.5%----14.9%
FCF/Rev LTM18.0%30.6%----24.3%
FCF/Rev 3Y Avg7.1%19.2%----13.1%

Valuation

NAGEVRTXAPMBBOTGDTCHINDMedian
NameNiagen B.Vertex P.Aptorum BridgeBi.CytoMed .Vyome  
Mkt Cap0.6107.8----54.2
P/S4.89.4----7.1
P/EBIT33.824.5----29.2
P/E31.829.6----30.7
P/CFO26.628.0----27.3
Total Yield3.1%3.4%----3.3%
Dividend Yield0.0%0.0%----0.0%
FCF Yield 3Y Avg-2.1%----2.1%
D/E0.00.0----0.0
Net D/E-0.1-0.0-----0.1

Returns

NAGEVRTXAPMBBOTGDTCHINDMedian
NameNiagen B.Vertex P.Aptorum BridgeBi.CytoMed .Vyome  
1M Rtn-23.8%7.2%-27.2%3.6%8.0%7.7%5.4%
3M Rtn-24.0%-8.1%-5.2%-14.4%--6.6%
6M Rtn-6.0%-15.8%59.8%--6.5%--6.2%
12M Rtn--11.6%5.0%--3.4%--3.4%
3Y Rtn-34.6%-76.8%----21.1%
1M Excs Rtn-11.5%2.2%-34.2%-1.9%5.3%-0.2%-1.1%
3M Excs Rtn-30.7%-18.5%-2.1%-8.1%--10.3%
6M Excs Rtn-27.7%-37.6%38.0%--28.3%--28.0%
12M Excs Rtn--29.0%-17.8%--33.2%--29.0%
3Y Excs Rtn--41.0%-151.9%----96.5%

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/6/20255/7/20253/4/202510/31/20248/7/20245/8/20243/6/202411/8/20238/9/20235/10/20233/8/202311/2/2022
Key Financials Quarterly            
Total Revenue313029262322211920232117
Ebitda45720-00-1-2-2-1-3
Operating Income3572-0-1-0-1-2-2-1-3
Net Income4572-0-00-1-2-2-1-1
EPS0.050.070.090.020.00-0.010.00-0.01-0.03-0.03-0.02-0.01
Key Financials TTM            
Total Revenue TTM116108100928683848381777269
Ebitda TTM181592-1-3-4-5-7-11-17-21
Operating Income TTM171380-2-4-6-7-9-13-19-22
Net Income TTM181491-1-4-5-6-6-11-17-20
Growth Rates Quarterly            
Total Revenue Growth36.8%37.6%37.4%31.2%11.9%-1.8%1.0%14.3%21.5%30.7%18.2%-1.4%
EBITDA Growth3005.3%1607.3%3543.4%381.5%106.1%77.7%120.7%73.3%68.6%78.7%79.9%68.9%
Operating Income Growth1344.1%752.8%4332.7%239.7%88.9%62.9%88.4%62.6%63.7%74.5%72.8%65.3%
Net Income Growth24160.0%1129.1%6197.4%295.8%99.3%74.1%108.0%2.6%65.7%75.4%73.4%88.9%
Margins Quarterly            
EBITDA Margin11.4%16.9%25.6%7.7%0.5%-1.5%1.0%-3.6%-9.2%-6.8%-4.7%-15.3%
Operating Income Margin10.2%15.7%24.4%6.3%-1.1%-3.3%-0.8%-5.9%-11.4%-8.7%-6.9%-18.0%
Net Income Margin11.6%16.6%24.6%7.3%-0.1%-2.2%0.5%-4.9%-10.8%-8.4%-6.8%-5.8%
Cash & Debt            
Total Cash605545322827272726232013
Total Debt343333344444
Net Debt / (Cash)-57-52-42-29-25-24-24-23-22-19-16-9
Cash Flows Quarterly            
FCF from Operations1893-001033-0-4
Cash Flows TTM            
FCF from Operations TTM212012415762-5-15-20
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC6.8%10.2%15.3%3.3%-0.5%-1.5%-0.3%-2.4%-4.8%-4.0%-2.9%-6.2%
Return on Invested Capital (ROIC) TTM            
ROIC TTM9.2%7.3%4.2%0.2%-1.2%-2.2%-2.9%-3.5%-4.5%-6.5%-9.4%-11.5%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Consumer Products segment7060574736
Ingredients segment119796
Analytical Reference Standards and Services segment33334
Corporate and other00   
Total8472675946


Operating Income by Segment
$ Mil20242023202220212020
Consumer Products segment147660
Ingredients segment54452
Analytical Reference Standards and Services segment-1-0-0-00
Corporate and other-25-28-36-31-34
Total-6-19-27-20-31


Short Interest

Short Interest: As Of Date10152025
Short Interest: Shares Quantity4,172,117
Short Interest: % Change Since 930202511.2%
Average Daily Volume1,532,065
Days-to-Cover Short Interest2.72
Basic Shares Quantity79,249,000
Short % of Basic Shares5.3%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/6/20252.2%7.7%0.1%
3/4/2025  �
10/31/2024   
8/7/2024   
3/6/2024   
11/8/2023   
8/9/2023   
3/8/2023   
...
SUMMARY STATS   
# Positive112
# Negative171716
Median Positive2.2%7.7%0.1%
Median Negative   
Max Positive2.2%7.7%0.1%
Max Negative   

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025806202510-Q 6/30/2025
3312025507202510-Q 3/31/2025
12312024304202510-K 12/31/2024
93020241031202410-Q 9/30/2024
6302024807202410-Q 6/30/2024
3312024508202410-Q 3/31/2024
12312023306202410-K 12/31/2023
93020231108202310-Q 9/30/2023
6302023809202310-Q 6/30/2023
3312023510202310-Q 3/31/2023
12312022308202310-K 12/31/2022
93020221102202210-Q 9/30/2022
6302022810202210-Q 6/30/2022
3312022512202210-Q 3/31/2022
12312021314202210-K 12/31/2021
93020211103202110-Q 9/30/2021

Insider Activity

Expand for More

 

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.